(#56) Real-World Evidence of Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for the Treatment of Tardive Dyskinesia in the United States

Abstract: Background: Deutetrabenazine is approved by the Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This study aimed to explore patient-reported ease of use, effectiveness, and satisfaction with once-daily (QD) deutetrabenazine extended-release tablets in patients with TD/HD. Methods: This noninterventional, prospective, cross-sectional, institutional review boardñapproved survey included adults with TD/HD taking deutetrabenazine QD. Participants in the Teva Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible. Consenting participants received study materials by mail/email. TD cohort results are reported here. Results: Among 209 participants with TD (mean age 59.7 years, 74% female, 91% White), 48% reported no prior TD medication. 83% liked that their doctor could increase/decrease their dose. 76% reported that their extra movements were very much/much improved with deutetrabenazine QD; >78% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements has improved their comfort in social settings and emotional well-being. 58% and 52% strongly agreed/agreed that reduction in their extra movements has improved their overall physical health and work/school life, respectively. 99% reported it was very/somewhat easy to take deutetrabenazine QD. Most (97%) strongly agreed/agreed that they will continue taking deutetrabenazine QD; 89% reported satisfaction with deutetrabenazine QD. Conclusion: Most participants reported satisfaction with deutetrabenazine QD, with flexible dosing making the medication easy to use and include in daily routines. Most participants reported improvements in extra movements since starting deutetrabenazine QD, leading to positive impacts on several quality-of-life domains.Short Description: Adults with tardive dyskinesia (TD) taking once-daily (QD) deutetrabenazine extended-release tablets (Nf209) completed a survey to explore patient-reported ease of use, effectiveness, and satisfaction during real-world use of deutetrabenazine QD. Most participants (76%) reported that extra movements were either very much improved or much improved with deutetrabenazine QD. 83% liked that their doctor could increase/decrease their dose. 89% reported satisfaction with deutetrabenazine QD and 97% expressed interest in continuing treatment.Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC.